Abstract
CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes. Of the 11 eligible patients enrolled in the phase I study in Japan, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m2 x 4 weekly infusions. The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61%(37/61) and 46%(6/13), respectively. Rituximab is a novel, effective anti-lymphoma agent with acceptable toxicities.
MeSH terms
-
Animals
-
Antibodies, Monoclonal* / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / immunology
-
Antineoplastic Agents* / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Japan
-
Lymphoma, B-Cell / drug therapy*
-
Mice
-
Prednisone / administration & dosage
-
Radioimmunotherapy
-
Recombinant Fusion Proteins
-
Rituximab
-
Treatment Outcome
-
United States
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
Recombinant Fusion Proteins
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone